OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Center for Biologics Evaluation and Research
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Laboratory of Immunobiochemistry Site Visit
The NVPO Unmet Needs Program: FY 2006 Update Ben Schwartz National Vaccine Program Office National Vaccine Advisory Committee Meeting, June 2006.
The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
Division of Bacterial, Parasitic and Allergenic Products Jay E. Slater, MD Director, DBPAP 25 October 2013.
Office of Biotechnology Products
The Agricultural Research Service Steven R. Shafer Deputy Administrator Natural Resources and Sustainable Agricultural Systems.
Overview of the Division of Viral Products
Overview of the Division of Viral Products VRBPAC Presentation of the Site Visit Report for the Laboratories of Retrovirus Research, Immunoregulation,
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Michael J. Brennan, Ph.D. for Kathryn M. Carbone, M.D. Associate Director for.
Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.
Advanced Vaccine Development: the Challenge is in the Details
Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
Associate Director for Research, OCTGT
OFFICE OF AIDS RESEARCH DHHS/NIH/OAR NIH AIDS Research Priorities Jack Whitescarver, Ph.D. NIH Associate Director for AIDS Research and Director, OAR May.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Division of Hematology Basil Golding M.D. Division Director Site Visits 2010 Laboratories of Hemostasis, and Plasma Derivatives.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Raj K. Puri, M.D., Ph.D. Director, DCGT
Strategic Issues in Vaccine Research (SIVR) Program Update, 2007 Ben Schwartz, NVPO NVAC June 2007.
1 Overview of the Laboratory of Hepatitis Viruses March 20, 2014 VRBPAC Discussion of the December 5, 2013 Site Visit for the Laboratory of Hepatitis Viruses.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.
Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Enter Title of Presentation on Master Slide U.S. Department of Health and Human Services Office of the Assistant Secretary for Public Health Emergency.
FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.
The Integrated National Biodefense Portfolio Initiative “One-Portfolio” Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF) May 6, 2009.
Division of Hematology Emergency Preparedness Action Initiatives Prepared by Mark Weinstein, Ph.D., Dorothy Scott M.D. and Basil Golding M.D. Division.
Laboratory of Methods Development and Quality Control Laboratory Overview September 22, 2005.
FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.
“28,424 cases of Ebola and still counting—what have we learned
OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,
Office of Vaccines Research and Review
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Introduction to FDA’s Office of Vaccines Research and Review Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review.
CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.
Overview Laboratory of Bacterial Polysaccharides From cover - Science, 23 March, 2001.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
The National Vaccine Plan Update: Recent Activities and Next Steps Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human.
Peer Review of OBP Research Division of Monoclonal Antibodies
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Division of Cellular and Gene Therapies (DCGT)
The NVPO Unmet Needs Program: Looking Back and Moving Forward Ben Schwartz National Vaccine Program Office National Vaccine Advisory Committee Meeting,
OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.
CBER Research: OCTGT Office Site Visit Carolyn A. Wilson, Ph.D. Associate Director of Research (Acting) CBER/FDA.
NIH Guidelines for Research Involving rDNA Molecules (NIH Guidelines) and Institutional Biosafety Committees.
1 |1 | Regulatory authority and Immunization programs: a joint work for patient safety Global Vaccine Safety Group Department of Essential Medicines and.
CBER: PDUFA IV Meeting Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research 11/14/05.
David M. Murray, Ph.D. Associate Director for Prevention Director, Office of Disease Prevention Multilevel Intervention Research Methodology September.
Partnerships for Pandemic & Bioterrorism Incidents
Expert Panel: Todd Damrow Cheryl Juntunen Susan Keady Michael Skeels
How Vaccines work.
Presentation transcript:

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site Visit May 19, 2006

CBER OVRR CBER ADR OVRR ADR Division Directors Research Reviewers

OVRR Laboratory Mission and Function Ensure the safety and efficacy of vaccines and related biological products for human use –Bacterial vaccines –Viral vaccines –Parasitic vaccines –Allergenic products Facilitate the development, evaluation, licensure and use of new vaccines and related products that positively impact the public health

Prioritizing Research Efforts within OVRR I. Address Regulatory Issues for Approved Products II. Anticipate Regulatory Issues for New Products III. Respond to Public Health Emergencies IV. Maintain Necessary Scientific Expertise V. Implement Recommendations from External Reviews

I. Address Regulatory Issues for Approved Products VACCINESCIENTIFIC EXPERTISE DBPAP DTAcP Pertussis, Bacterial toxins, serological assays Pneumococcal Polysaccharide conjugation, human Haemophilus serological assays, outer membrane proteins Meningococcal DVP Influenza Flu virology, potency assays Polio, Flu Cell Substrate program- identify adventitious agents, oncogenes, new cell lines Prioritizing Research:

II.Anticipate Regulatory Issues for New Products VACCINESCIENTIFIC RESPONSE DVP HIV Discovery of novel HIV peptides for discriminating HIV infection from immunization with new vaccines DBPAP Meningococcal New polysaccharide conjugation technology transferred to Meningococcal Vaccine Initiative TB Post-infection assay to evaluate Safe use of new TB vaccines in Infected individuals. Prioritizing Research:

III. Respond to Public Health Emergencies VACCINESCIENTIFIC RESPONSE Counterterrorism Developing Assays and Animal Models to evaluate vaccines for Anthrax, Tularemia, Smallpox, etc Immune assays to measure potency of new CT vaccines Pandemic FluAvian flu libraries, non-egg based technologies, broad coverage vaccines Prioritizing Research:

Workshops Co-sponsored by OVRR “Assaying Potency of Novel Vaccines” with DAIDS, DMID, VRC October 2005, Bethesda, MD “The 14th International Pathogenic Neisseria Conference”, September 2004, Milwaukee, WI “NIAID/NIH – CBER/FDA TB Vaccine Regulatory Workshop”, December 2003, Bethesda, MD “Fourth International Conference on Tularemia”, September Bath, UK Global Activities WHO Collaborating Center – eg. annual Flu strain selection, TB standards WHO/PAHO Expert Advisors BioTechnology Engagement Program [Former Soviet Union collaborations] CBER Global Vaccine Initiative OVRR OUTREACH ACTIVITIES

Sources of Funding for OVRR Research National Vaccine Program Office Awards - 6 in FY 05, 4 in FY 06 Biodefense related awards – ORDC, DARPA, DOD - 9 ORDC in FY 06 Intraagency Agreements – NIH, CDC - Cell Substrates IAA w NIAID CRADAs – Universities, Foundations - TB assay, AERAS Foundation

Evaluation of OVRR Research Programs Performed on at least an annual basis Process begins in Divisions -Evaluation of PI Res Prog by Lab Chief-Division Director -Evaluates research progress (pubs; presentations; outreach) and Regulatory Workload (INDs, BLAs, Meetings w/ Pharma) Evaluation of Division Research Programs by OVRR to address: - FDA regulatory needs - emerging issues - future issues ( years ) -recommendations made by external Advisory groups Individual PIs evaluated for promotions by CBER PCE committee

Major Challenges to OVRR Management: Expansion / Recruitment Promoting Outstanding Junior Scientists Limited opportunities for outside funding Travel to scientific meetings Communication of research successes [visibility]

COMMUNICATION

Researcher-Reviewer Model provides OVRR with: First hand experience with latest technologies applied to biologics Ability to assess risks of new vaccines and therapies Ability to provide a timely response to new or emergency issues Anticipate future needs Suggest new approaches Develop assays Enhanced ability to interact with Pharma, NGOs, WHO, & HHS agencies Ability to retain staff # based on 1998 Science Board Report for Review of CBER Research